Skip to main content

Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus

Current Diabetes Reports volume 19, Article number: 54 (2019) Cite this article

Abstract

Purpose of Review

There is consensus that metformin should be the first-line pharmacological therapy for type 2 diabetes. Although new evidence on effective treatments for type 2 diabetes is rapidly evolving, there is uncertainty regarding the optimal choice of second-line therapy. Our aim was to review the current major guidelines for second-line therapy in type 2 diabetes, along with findings from the recent cardiovascular outcome trials, focusing on two particularly promising classes of glucose-lowering drugs, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP1 RAs).

Recent Findings

In the recent randomized controlled trials, two SGLT2 inhibitors (i.e., empagliflozin and canagliflozin) and two GLP1 RAs (i.e., liraglutide and albiglutide) reduced cardiovascular events in patients with type 2 diabetes, of whom most had established atherosclerotic cardiovascular disease. Some clinical guidelines have changed their recommendations for second-line therapy based on these findings. The first choice for a second-line therapy by the new American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) guidelines is SGLT2 inhibitors or GLP1 RAs for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. For patients without these conditions, the ADA/EASD lists five options of noninsulin second-line therapy without a suggested hierarchy of use. On the other hand, the 2019 consensus statement from the American Association of Clinical Endocrinologists/American College of Endocrinology lists nine hierarchical options, with GLP1 RAs as the first recommended therapy, followed by SGLT2 inhibitors and dipeptidyl peptidase 4 (DPP4) inhibitors, and sulfonylurea as the last option. The American College of Physicians recommends four oral treatment options, which do not include GLP1 RAs. The International Diabetes Federation recommends sulfonylureas, DPP4 inhibitors, or SGLT2 inhibitors as preferred second-line drugs with GLP1 RAs as an alternative in obese patients. The World Health Organization strongly recommends sulfonylureas in low-resource settings. The National Institute for Health and Care Excellence in the UK recommends DPP4 inhibitors, thiazolidinediones, or sulfonylureas, with use of SGLT2 inhibitors only under special circumstances.

Summary

Clinical guidelines for the choice of second-line therapy in type 2 diabetes are inconsistent. A comprehensive assessment of the risks and benefits of second-line therapy is needed to address knowledge gaps that underlie core clinical practice.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabres.2018.02.023.

    CAS  Article  Google Scholar 

  2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017.

    Google Scholar 

  3. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44. https://doi.org/10.2337/dc12-0002.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–50. https://doi.org/10.1001/jama.291.7.844.

    CAS  Article  PubMed  Google Scholar 

  5. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73. https://doi.org/10.1161/01.cir.0000437741.48606.98.

    Article  PubMed  Google Scholar 

  6. Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55(1):66–76. https://doi.org/10.1007/s12020-016-1014-6.

    Article  Google Scholar 

  7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. https://doi.org/10.2337/dci18-0007.

    Article  PubMed Central  Google Scholar 

  8. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–S102. https://doi.org/10.2337/dc19-S009.

    Article  Google Scholar 

  9. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract. 2019;25(1):69–100. https://doi.org/10.4158/CS-2018-0535.

    Article  Google Scholar 

  10. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701. https://doi.org/10.2337/dci18-0033.

    Article  PubMed  Google Scholar 

  11. Qaseem A, Barry MJ, Humphrey LL, Forciea MA. Clinical Guidelines Committee of the American College of P. oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279–90. https://doi.org/10.7326/M16-1860.

    Article  PubMed  Google Scholar 

  12. International Diabetes Federation. Recommendations for managing type 2 diabetes in primary care, 2017. www.idf.org/managing-type2-diabetes. Accessed 14 Apr 2019.

  13. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–25. https://doi.org/10.1007/s00125-016-4157-3.

    CAS  Article  PubMed  Google Scholar 

  14. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.

    CAS  Article  Google Scholar 

  15. •• Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099. https://doi.org/10.1056/NEJMc1712572. Findings from the CANVAS program suggest that canagliflozin reduces a risk of cardiovascular events, but increases a risk of amputation in patients with type 2 diabetes and an elevated risk of cardiovascular disease.

  16. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.

    CAS  Article  Google Scholar 

  17. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72(24):3200–23. https://doi.org/10.1016/j.jacc.2018.09.020.

    Article  Google Scholar 

  18. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9. https://doi.org/10.1016/S0140-6736(18)32590-X.

    CAS  Article  Google Scholar 

  19. National Institutes of Health. Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (Dapa-HF). Identifier: NCT03036124. https://www.clinicaltrials.gov. Accessed 15 Apr 2019.

  20. National Institutes of Health. EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure with preserved ejection fraction (EMPEROR-Preserved). Identifier: NCT03057951. https://www.clinicaltrials.gov. Accessed 15 April 2019.

  21. National Institutes of Health. EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure with reduced ejection fraction (EMPEROR-reduced). Identifier: NCT03057977. https://www.clinicaltrials.gov. Accessed 15 Apr 2019.

  22. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925.

    CAS  Article  Google Scholar 

  23. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34. https://doi.org/10.1056/NEJMoa1515920.

    CAS  Article  Google Scholar 

  24. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017;46(6):462–72. https://doi.org/10.1159/000484633.

    CAS  Article  Google Scholar 

  25. •• Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1811744. Findings from the CREDENCE trial suggest that canagliflozin reduces the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and kidney disease.

    CAS  Article  Google Scholar 

  26. Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018;11(6):749–61. https://doi.org/10.1093/ckj/sfy090.

    Article  Google Scholar 

  27. National Institutes of Health. A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD). Identifier: NCT03036150. https://www.clinicaltrials.gov. Accessed 15 Apr 2019.

  28. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19–28. https://doi.org/10.1177/2042018814559725.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. •• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827. Findings from the LEADER trial suggest that liraglutide reduces a risk of cardiovascular events in patients with type 2 diabetes; most of whom had established atherosclerotic cardiovascular disease.

    CAS  Article  Google Scholar 

  30. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39. https://doi.org/10.1056/NEJMoa1612917.

    CAS  Article  PubMed  Google Scholar 

  32. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. https://doi.org/10.1056/NEJMoa1509225.

    CAS  Article  PubMed  Google Scholar 

  33. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.

    CAS  Article  PubMed  Google Scholar 

  34. Bain SC, Mosenzon O, Arechavaleta R, Bogdanski P, Comlekci A, Consoli A, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499–508. https://doi.org/10.1111/dom.13553.

    CAS  Article  PubMed  Google Scholar 

  35. Company announcement: oral semaglutide demonstrates a favourable cardiovascular safety profile and a significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial. https://www.novonordisk.com/bin/getPDF.2226789.pdf. Accessed 14 Apr 2019.

  36. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77. https://doi.org/10.1002/ejhf.657.

    CAS  Article  PubMed  Google Scholar 

  37. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–8. https://doi.org/10.1001/jama.2016.10260.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42–9. https://doi.org/10.1111/dom.13028.

    CAS  Article  PubMed  Google Scholar 

  39. Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48. https://doi.org/10.1056/NEJMoa1616011.

    CAS  Article  PubMed  Google Scholar 

  40. Bethel MA, Mentz RJ, Merrill P, BUSE JB, Chan JC, Goodman SG, et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 2018;67(Supplement 1):522–P. https://doi.org/10.2337/db18-522-P.

    Article  Google Scholar 

  41. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859–69. https://doi.org/10.1016/S2213-8587(18)30268-7.

    CAS  Article  PubMed  Google Scholar 

  42. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35. https://doi.org/10.1016/S0140-6736(09)60953-3.

    CAS  Article  PubMed  Google Scholar 

  43. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89. https://doi.org/10.1016/S0140-6736(05)67528-9.

    CAS  Article  PubMed  Google Scholar 

  44. Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1(5):e002279. https://doi.org/10.1161/JAHA.112.002279.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352.

    CAS  Article  PubMed  Google Scholar 

  46. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. https://doi.org/10.1056/NEJMoa1307684.

    CAS  Article  PubMed  Google Scholar 

  47. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. https://doi.org/10.1056/NEJMoa1305889.

    CAS  Article  PubMed  Google Scholar 

  48. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. https://doi.org/10.1001/jama.2018.18269.

    CAS  Article  PubMed  Google Scholar 

  49. FDA. Endocrinologic and Metabolic Drug Advisory Committee. 2008; Day 2, Part 1 (1–100).

  50. FDA. Endocrinologic and Metabolic Drug Advisory Committee. 2008; Day 2, Part 2 (101–200).

  51. FDA. Endocrinologic and Metabolic Drug Advisory Committee. 2008; Day 2, Part 3 (201–300).

  52. Taylor SI, Leslie BR. Cardiovascular outcome trials of diabetes drugs: lessons learned. J Clin Invest. 2018;128(3):893–6. https://doi.org/10.1172/JCI99820.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254–61. https://doi.org/10.2337/dc13-0356.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. World Health Organization. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. 2018. https://www.who.int/diabetes/publications/guidelines-diabetes-medicines/en/. Accessed 15 Apr 2019.

  55. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4(Suppl 1):S11–8. https://doi.org/10.1016/S1751-9918(10)60004-6.

    Article  PubMed  Google Scholar 

  56. Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) JAPAN study. PLoS One. 2012;7(6):e36361. https://doi.org/10.1371/journal.pone.0036361.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. National Institute for Health and Care Excellence. Managing blood glucose in adults with type 2 diabetes: NICE Pathways. 2019. https://pathways.nice.org.uk/pathways/type-2-diabetes-in-adults#path=view%3A/pathways/type-2-diabetes-in-adults/managing-blood-glucose-in-adults-with-type-2-diabetes.xml&content=view-index. Accessed 15 Apr 2019.

  58. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management: evidence reviews for SGLT-2 inhibitors and GLP-1 mimetics. 2018. https://www.nice.org.uk/guidance/ng28/evidence/march-2018-evidence-reviews-for-sglt2-inhibitors-and-glp1-mimetics-pdf-4783687597. Accessed 15 Apr 2019.

Download references

Funding

This project is funded by NIH.

Author information

Affiliations

  1. Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA

    Jung-Im Shin

  2. The Welch Center for Prevention, Epidemiology, and Clinical Research, 2024 E. Monument Street, Suite 2-600 (Rm 2-203), Baltimore, MD, 21287, USA

    Jung-Im Shin

Authors
  1. Jung-Im Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jung-Im Shin.

Ethics declarations

Conflict of Interest

The author declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Diabetes Epidemiology

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shin, JI. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus. Curr Diab Rep 19, 54 (2019). https://doi.org/10.1007/s11892-019-1171-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-019-1171-0

Keywords

  • Second-line glucose-lowering therapy
  • Type 2 diabetes mellitus
  • Clinical guidelines
  • Cardiovascular outcome trials